A Prosperity Partnership for the Design of Next-Generation Antibody Drug Bioconjugates (Next-Gen ADC)

葛兰素史克(GSK)是一家全球领先的医疗保健公司，发现、开发和生产治疗呼吸系统疾病、癌症、心脏病和牛皮癣等皮肤疾病的药物。葛兰素史克每年生产超过40亿包药品，目标是应对社会医疗保健的重大挑战。葛兰素史克不断寻求提高新药的效率、疗效和可持续性。GSK感兴趣的一个领域是扩大他们的抗体药物结合物(ADC)产品组合。抗体-药物结合物是一种基于将抗体附着到小分子药物上的杂交药物，它提高了药物的靶向性。ADC结合了将药物输送到患病细胞和组织的能力，这是一种令人感兴趣的药物有效载荷。与传统药物相比，ADC的优势在于它们有可能通过只将药物输送到身体的患病部位来减少与药物相关的副作用。这一繁荣伙伴关系旨在建立在葛兰素史克和斯特拉斯克莱德大学(UOS)之间现有的充满活力的合作基础上。将利用每个合作伙伴的优势来提供一系列新的方法和途径，以应对ADC和更广泛的生物结合物的发现、开发和应用中的一些主要挑战。我们的愿景是提高发现ADC并将其转化为未来药物的效率，从而减少制造新药所需的时间和精力。我们的方法和研究将意味着变革性的新ADC将以更低的成本和更快的生产速度制造出来，并以更快的速度转化为新药。我们的合作伙伴关系涵盖的两个关键挑战领域包括：1.整个ADC实验分析领域的数据采集的管理和标准化。在设计ADC时使用数据通常受到个别公司的保护，研究人员无法访问。我们将开发一个标准化的数据分析平台，为伙伴关系接近尾声的人工智能知情决策过程奠定基础。这将有助于更广泛的制药业和学者成功地设计基于ADCS的新药。制造下一代ADC。新的ADC的发现和发展需要有效和灵活的化学反应将药物与抗体联系起来。我们将开发一套新试剂工具箱，以方便更便捷和简化的ADC制备。通过整合项目的各个科学主题，以及葛兰素史克和斯特拉斯克莱德大学的专业知识，我们将为更广泛的制药和生物技术部门做出重大贡献。我们还将培训和发展下一代药物发现劳动力，他们将开发基于ADC的未来药物。最后，这一伙伴关系的一个关键成果将是帮助葛兰素史克实现其使命，即更快地发现和开发变革性药物，帮助人们做更多事情，感觉更好，活得更长。

GlaxoSmithKline (GSK) is a leading global healthcare company that discovers, develops and manufactures medicines for respiratory disorders, cancer, heart disease, and skin conditions like psoriasis. GSK manufactures over 4 billion packs of medicines each year, with the goal of addressing society's healthcare grand challenges. GSK continually seeks to improve the efficiency, efficacy and sustainability of new medicines. One area of interest to GSK is the expansion of their antibody drug conjugate (ADC) portfolio. Antibody-drug conjugates are hybrid medicines based on attaching antibodies to small molecule drugs, which improves the targeting of the medicine. ADCs combine the ability to deliver medicines to diseased cells and tissues a drug payload of interest. The advantage of ADCs over conventional medicines is they have the potential to reduce side effects associated with a drug by only delivering the it to the diseased parts of the body. This Prosperity Partnership aims to build on an existing vibrant collaboration between GSK and the University of Strathclyde (UoS). The strengths of each partner will be leveraged to deliver a range of new methods and approaches to address some of the major challenges in the discovery, development, and application of ADCs and a broader array of bioconjugates. Our vision is to increase the efficiency of discovering and turning ADCs into future medicines in terms of the time and energy it takes to make new medicines. Our approaches and research will mean that transformative new ADCs will be made at lower costs, with a greater speed of production, and turn into new medicines at a much faster pace.The two key challenge areas covered in our partnership include: 1. The curation and standardisation of data acquisition across the entire landscape of experimental analysis of an ADC. The use of data in designing ADCs is usually protected by individual companies and are not accessible to researchers. We will develop a standardised data analytical platform that forms the basis for an artificial intelligence informed decision-making process towards the end of the partnership. This will help the broader pharmaceutical industry and academics to successfully design new medicines based on ADCs.2. Making Next generation ADCs. The discovery and development of new ADCs require efficient and flexible chemical reactions to link drugs to antibodies. We will develop a toolbox of new reagents to facilitate the more expedient and streamlined preparation of ADCs. Through integrating the individual scientific themes of the projects, and the expertise from both GSK and the University of Strathclyde, we will make a major contribution to the wider pharmaceutical and biotechnology sectors. We will also train and develop the next generation of the drug discovery workforce that will develop future medicines based on ADCs. Finally, a key outcome of this partnership will be to assist GSK in achieving its mission of discovering and developing transformative medicines faster to help people do more, feel better, and live longer.